CHEN W Q, ZHENG R S, BAADE PETER D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[2]
Chinese Society of Clinical Oncology(CSCO). Guidelines for the Diagnoses and Treatment of Primary Breast Cancer[中国临床肿瘤学会(CSCO)原发性乳腺癌诊疗指南][M]. Beijing: People's Medical Published House, 2018.
[3]
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer. (Version 3.2020).
[4]
SEIDMAN A D. Gemcitabine as single-agent therapy in the management of advanced breast cancer[J]. Oncology (Williston Park), 2001, 15(2 suppl 3):11-14.
[5]
ZELEK L, BARTHIER S, RIOFRIO M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma[J]. Cancer, 2001, 92(9):2267-2272.
[6]
SEIDMAN A D, TIERSTEN A, HUDIS C, et al. Phase Ⅱ trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer[J]. J Clin Oncol, 1995,13(10):2575-2581.
[7]
CITRON M L, BERRY D A, CIRRINCIONE C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial9741[J]. J Clin Oncol, 2003, 21(8):1431-1439.
[8]
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Antiemesis. (Version 1.2019). [EB/OL].2019.[2020-03-23]. https://www.nccn.org/professionals/physician_gls/default.aspx.
[9]
JONES S E, SAVIN M A, HOLMES F A, et al.Phase Ⅲ trial comparing doxorubicin plus cyclophosphamide with docetaxel pluscyclophosphamide as adjuvant therapy for operable breast cancer[J]. J Clin Oncol, 2006, 24(34):5381-5387.
[10]
JONES S, HOLMES F A, O'SHAUGHNESSY J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735[J]. J Clin Oncol, 2009,27(8):1177-1183.
[11]
Expert Committee on Rational Drug Use of National Health Commission. Guidelines for Rational Use of Breast Cancer(乳腺癌合理用药指南) [M]. Beijing: People's Medical Publishing House,2019.
[12]
SLAMON D, EIERMANN W, ROBERT N, et al. Phase Ⅲ randomized trial comparing doxorubicin and cyclopho-sphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study[C]. San Antonio:San Antonio Breast Cancer Symposium,2005.
[13]
ROBERT N J, EIERMANN W, PIENKOWSKI T, et al. BCIRG 006: docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: quality of life (QOL) at 36 months follow-up[J]. Asco Meeting Abstracts, 2007, 25(18S):19647.
[14]
NORTON L, SLAMON D, LEYLAND-JONES B, et al. Overall survival advantage to simultaneous chemotheraphy plus the humanized anti-HER-2 monoclonal antibody Herceptin in HER-2 monoclonal antibody Herceptin in HER-2 overexpressing metastatic breast cancer[J]. Proc Am Soc Clin Oncol, 1999,18:127a.
[15]
SEIDMAN A D, BERRY D, CIRRINCIONE C, et al. Randomized phase Ⅲ trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and leukemia group B protocol 9840[J]. J Clin Oncol, 2008,26(10):1642-1649.
[16]
SCHNEEWEISS A, CHIA S, HICKISH T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase Ⅱ cardiac safety study (TRYPHAENA) [J]. Ann Oncol, 2013, 24(9):2278-2284.
[17]
GEYER C, FORSTER J, LINDQUIST D, et al. Lapatinib plus capecitabine for HER-2-positive advanced breast cancer[J]. N Engl J Med, 2006,355(26):2733-2743.
[18]
CAULFIELD S E, DAVIS C C, BYERS K F. Olaparib: a novel therapy for metastatic breast cancer in patients with a BRCA 1/2 mutation[J]. J Adv Pract Oncol, 2019, 10(2):167-174.
[19]
LE D, GELMON K A. Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer[J]. Expert Rev Clin Pharmacol, 2018, 11(9):833-839.
[20]
EIERMANN W, PAEPKE S, APPFELSTAEDT J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study[J]. Ann Oncol, 2001, 12(11):1527-1532.
[21]
BIG 1-98 Collaborative Group, MOURIDSEN H, GIOBBIE-HURDER A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer[J]. N Engl J Med, 2009, 361(8):766-776.
[22]
ELLIS M J 1, SUMAN V J, HOOG J, et al. Randomized phase Ⅱ neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031[J]. J Clin Oncol, 2011, 29(17):2342-2349.
[23]
ROBERTSON J F, LINDEMANN J P, LLOMBART-CUSSAC A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study[J]. Breast Cancer Res Treat, 2012, 136(2):503-511.
[24]
ELLIS M J, LLOMBART-CUSSAC A, FELTL D, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase Ⅱ FIRST study[J]. J Clin Oncol, 2015, 33(32):3781-3787.
[25]
PARIDAENS R J, DIRIX L Y, BEEX L V, et al. Phase Ⅲ study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group[J]. J Clin Oncol, 2008, 26(30):4883-4890.
[26]
DE GLAS N A, FONTEIN D B, BASTIAANNET E, et al. Physical activity and survival of postmenopausal, hormone receptor-positive breast cancer patients: results of the tamoxifen exemestane adjuvant multicenter lifestyle study[J]. Cancer, 2014, 120(18):2847-2854.
[27]
FINN R S, MARTIN M, RUGO H S, et al. Palbociclib and letrozole in advanced breast cancer[J]. N Engl J Med, 2016, 375(20):1925-1936.
2020, Vol. 55 
